![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 37, 26141-26148, September 10, 1999
§,
,
,
,
,
, and
**
From the Departments of
Dermatology and
¶ Cytogenetics, Stanford University School of Medicine, Stanford,
California 94305-5486 and
Geron Corp., Menlo
Park, California 94025-1130
| |
ABSTRACT |
|---|
|
|
|---|
Normal human endothelial cells, like other
somatic cells in culture, divide a limited number of times before
entering a nondividing state called replicative senescence. Expression
of the catalytic component of human telomerase, human telomerase
reverse transcriptase (hTERT), extends the life span of human
fibroblasts and retinal pigment epithelial cells beyond senescence
without causing neoplastic transformation (Bodnar, A. G.,
Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin,
G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and
Wright, W. E. (1998) Science 279, 349-352; Jiang, X.,
Jimenez, G., Chang, E., Frolkis, M., Kusler, B., Sage, M., Beeche, M.,
Bodnar, A., Wahl, G., Tlsty, T., and Chiu, C.-P. (1999) Nat.
Genet. 21, 111-114). Here, we show that both human large vessel
and microvascular endothelial cells also bypass replicative senescence
after introduction of hTERT. For the first time, we report that hTERT
expression in these life-extended vascular cells does not affect their
differentiated and functional phenotype and that these cells maintain
their angiogenic potential in vitro. Furthermore, hTERT(+)
microvascular endothelial cells have normal karyotype, and hTERT(+)
endothelial cell strains do not exhibit a transformed phenotype.
Relative to parental cells at senescence, hTERT-expressing endothelial
cells exhibit resistance to induction of apoptosis by a variety of
different conditions. Such characteristics are highly desirable for
designing vascular transplantation and gene therapy delivery systems
in vivo.
The integrity of endothelial cell
(EC)1 function is compromised
with advancing age and directly contributes to
age-dependent impairment of angiogenesis and development of
vascular diseases (1, 2). Aging of the vasculature is also associated
with a number of phenotypic and hemodynamic changes commonly observed in cardiovascular disease states (3, 4). Some of these phenotypic alterations have been found to occur in ECs undergoing senescence in vitro and include increased expression of proteolytic
activity (5, 6), inflammatory markers (7-9), and vasoconstrictors and
reduced expression of vasodilators and vasoprotective factors (3,
10-12).
The adult endothelium in vivo is remarkably quiescent (13,
14), but ECs can be activated to proliferate, e.g. following traumatic injury, inflammation, and tumor formation or in response to
physiologic cues during hair growth and ovarian cycling (15, 16). This
property has allowed the in vitro cultivation and expansion
of ECs from many different tissues. Like most human somatic cells,
however, ECs undergo replicative senescence in vitro after a
finite number of divisions, which can vary between 20 and 60 population
doublings (PDLs) depending on the tissue of origin and culture
conditions (17).
Efforts to extend the life of ECs have focused on ectopic expression of
viral oncogenes (18-21), spontaneous transformation (22), addition of
exogenous growth factors, and provision of supportive matrix components
(17). One EC-specific growth factor, vascular endothelial cell growth
factor has been shown to both delay the onset of human dermal
microvascular EC (HDMEC) senescence (23) and block anoikis (anchorage
disruption-induced apoptosis) by producing a permissive matrix that
supports EC adhesion and proliferation (24). ECs will eventually
undergo replicative senescence regardless of exogenous growth factors
and matrix components unless they are transformed. Immortal EC lines
generated by viral or spontaneous transformation, however, invariably
fail to exhibit physiologic distal proliferative signaling pathways and
eventually lose important differentiated EC functions.
Another way to bypass senescence has recently been achieved by ectopic
expression of the human telomerase reverse transcriptase (hTERT) gene,
which imparts replicative immortality to fibroblasts and retinal
pigment epithelial (RPE) cells (25) without converting to a neoplastic
transformed phenotype (26, 27). A recent finding that both hTERT
expression and inactivation of pRb or p16 is required to immortalize
primary human keratinocytes and mammary epithelial cells raises the
issue of cell type specificity in hTERT-mediated immortalization (28).
In this report, we show that both large and small vessel-derived ECs,
like dermal fibroblasts, can be effectively immortalized by hTERT alone
in the absence of malignant transformation. In addition, we show for
the first time that hTERT-immortalized ECs exhibit functional and
morphogenetic characteristics of parental cells. These hTERT-EC lines
may also display a survival advantage beyond the hurdling of
replicative senescence, as they appear to be more resistant to
programmed cell death. Such characteristics may be useful in the design
of vascular model systems and therapeutic stratagies for treating
age-related diseases of the vasculature.
Establishment of Endothelial Cell Cultures--
Human umbilical
vein endothelial cells (HUVECs) were given as a gift from Drs. Thomas
Maciag (Maine Medical Center) and Susan Garfinkel (American Red Cross).
Human saphenous vein endothelial cells (HSVECs) came from Vascular
Endothelial Cell (VEC) Laboratories. Human aortic endothelial cells
(HAECs), human coronary arterial endothelial cells (HCAECs), and part
of HDMECs for making hTERT1 were purchased from Clonetics. hTERT3 was
established in our laboratory by preparation of primary HDMECs from
neonatal foreskin as described previously (29, 30). Growth media were
from EBM-2 (or EBM) MV BulletKit (Clonetics). Our primary parental
HDMECs for hTERT3 was purified with PECAM-coated beads (Sigma) and
recovered with a magnetic particle concentrator (Promega). A
spontaneously transformed HUVEC line, ECV304, was obtained from ATCC.
Gene Transduction--
Gene transfer was achieved by either
electroporation-based transfection or retrovirus-mediated gene
transfer. For electroporation, pZeoSV-hTERT, a derivative of pZeoSV
(Invitrogen) was used to transfect HUVECs (25). Two different versions
of retroviruses were used to transduce hTERT genes to the ECs.
pBabe-hTERT (a generous gift from Dr. Woody Wright, University of Texas
Southwestern Medical Center, Dallas, TX) was used for HAECs, HCAECs,
and HSVECs (31) and LZRS-hTERT was used for HDMECs (32). The expression of hTERT for both retroviral vectors was driven by Mololey murine leukemia virus 5'-long terminal repeat promoter. Viral titers determined by the infection of NIH-3T3 cells with pBabe-hTERT or LZRS
vector containing enhanced green fluorescent protein reporter gene were
estimated at approximately 5 × 106/ml.
Telomeric Repeat Amplification Protocol (TRAP) Assay--
Either
a non-amplified conventional standard (33) or a PCR-ELISA-based assay
(Roche Molecular Biochemicals) was used to measure the telomerase
activity from the hTERT transgene or endogenous telomerase. The
standard protocol was used for HUVECs, HAECs, HCAECs and HSVECs,
whereas PCR-ELISA was used for HDMECs. For visualizing the DNA ladder
with the standard protocol, 1000 or 5000 cell equivalents were
analyzed. For PCR-ELISA, 2000 cell equivalents were used. The PCR-ELISA
protocol was provided by the assay kit manufacturer (Roche
Molecular Biochemicals).
Telomere Length Assay--
Isolation of genomic DNA and Southern
blot determination of mean terminal restriction fragment (TRF) were
performed according to published procedures (34-36). Briefly, genomic
DNA (3 µg) was digested with HinfI/RsaI and run
on 0.6% agarose gel. The gel was transferred onto a positively charged
nylon membrane, which was hybridized at 65 °C overnight.
Hybridization signals were detected by chemiluminescence or
radioactivity. Calculation of mean TRF length was done as described
previously (37)
RT-PCR for Telomerase Transcripts--
The primers for RT-PCR
were as follows: 1) in the hTERT gene, sense, CACCTCACCCACGCGAAAA;
antisense, CCAAAGAGTTTGCGACGCATGTT; and 2) at the border of hTERT and
retroviral LZRS sequence, sense, TCCTGAAAGCCAAGAACGCA;
antisense, GACCAACTGGTAATGGTAGCGA. Total RNA was isolated with
TRIZOL (Life Technologies, Inc.). The RT-PCR was performed by a
one-step RT-PCR system according to the manufacturer (Life
Technologies, Inc.).
Flow Cytometry--
The antibodies used for flow cytometry were
anti-PECAM-1 (Becton Dickinson), ICAM-1 (Pharmingen), and Apo2.7
(Immunotech). For stimulated expression studies (e.g.
ICAM-1, VCAM-1, and E-selectin) cells were stimulated with TNF- Matrigel and 3D Collagen Overlay Assays--
The procedure was
as follows. 1) Matrigel (Collaborative Biomedical Products) was placed
on ice and allowed to thaw overnight at 4 °C. 350 µl of Matrigel
was layered onto a prechilled well of a six-well plate and then placed
in an incubator at 37 °C for 30 min until solidified. Parental
HUVECs, transformed ECV304 cells, or hTERT-HUVECs (3.5 × 105 cells) in M199, 15% fetal bovine serum, 10 units/ml
heparin, 16 µg/ml endothelial cell growth factor (ECGF) (Roche
Biomolecules) were seeded onto the matrix and allowed to incubate at
37 °C in a 5% CO2 environment. 2) Primary or
hTERT-transduced HDMECs were overlaid with a 1:1 mixture of Vitrogen
100 (Collagen Biomaterials) and 2× Iscove's medium (Life
Technologies, Inc.). Solidification of the collagen gel occurred 30 min
after neutralization with NaOH, followed by incubation at 37 °C.
Plates were photographed at 8 and 24 h using a Zeiss inverted microscope.
Cell Death ELISA--
Cells were cultured in 48-well plates and
maintained at confluence for 2 days before the assay. The reagents and
protocols were from Roche Molecular Biochemicals. Briefly, plates were
centrifuged for 10 min at 200 × g, and supernatants
were removed. Cells were then lysed for 30 min at room temperature, and
plates were recentrifuged. 10% (v/v) of the supernatant was used for
incubation with anti-histone-biotin and anti-DNA-peroxidase. After
2 h of incubation, plates were washed three times and incubated
with substrate solution. The absorbance was measured at 405 nm with a
microplate reader (Bio-Rad).
Karyotype Analysis--
Following mitotic arrest with
Colcemid®, monolayer cell cultures in log-phase growth were harvested
by standard cytogenetic methods of trypsin dispersal, hypotonic shock
with 0.075 M KCl, and fixation with 3:1 methanol/acetic
acid fixative (39). Mitotic cells slide preparations were analyzed by
the GTW banding method (40).
Senescence-associated (SA) Uptake of DiI-acetylated LDL--
Primary and hTERT-infected ECs
were incubated in growth medium containing 10 µg/ml of DiI-labeled
acetylated LDL (Molecular Probes) for 4 h at 37 °C. The culture
plates were then observed under an inverted Zeiss microscopy equipped
with a rhodamine filter.
Western Blot Analysis for Retinoblastoma Protein
(pRb)--
Western analysis for pRb was performed as we previously
described (26). The antibody to pRb (PharMingen) recognizes both hyper-
and hypophosphorylated forms of the proteins.
Clonogenic Soft Agar Assay--
Cells were resuspended at 1 × 104 cells/ml in growth medium containing 0.36% agar
(Difco). Cell suspension (5 ml) was added to 60-mm plates (Costar)
precoated with 0.9% solid agar (5 ml). We counted colonies composed of
40 or more cells after 2-6 weeks.
hTERT Expression Extends EC Life Span--
Our previous studies
showed that ectopic expression of recombinant hTERT reconstituted
telomerase efficiently in both dermal fibroblasts and RPE (25). In the
present study, we have expressed hTERT in HUVECs by stable transfection
and in HAECs, HCAECs, HSVECs, and HDMECs by retroviral transduction.
The characteristic DNA ladder of the TRAP assay indicates specific
telomerase activity in a representative HUVEC-hTERT clone and
transduced HAEC-hTERT and HDMEC-hTERT mass cell cultures (Fig.
1A). A quantitative
PCR-ELISA-TRAP shows that telomerase activity of hTERT(+) HDMECs is
maintained for over 100 PDLs, and the level of telomerase activity
achieved in HDMECs is comparable to that expressed by the 293 human
embryonic kidney tumor cell line (Fig. 1B). By contrast,
parental HDMECs expressed a low level of endogenous telomerase
transiently at early PDLs, consistent with previous reports (42). Using
RT-PCR, we have also confirmed the presence of hTERT RNA transcribed
from the transduced retroviral vector at PDL 60 in HDMECs (data not shown).
Table I summarizes the maximal PDL number
attained for each of the five hTERT(+) EC lines. Different parental EC
strains senesced at different PDLs, exhibiting typical flattened cell morphology and unresponsiveness to growth factors (Fig.
2) and showed marked SA
To examine the effects of hTERT expression on EC telomeres, we assessed
telomere lengths by TRF Southern analysis (see under "Materials and
Methods"). Fig. 1C shows the change in telomere length of
hTERT(+) HDMEC mass cell cultures as a function of PDL. Telomere
shortening was observed up to PDL 100-120 followed by consistent
stabilization at approximately 3-4 kbp. Analysis in four different
hTERT-HUVEC clones showed similar results, with TRF stabilization at
approximately 2.5 kbp by PDL 100-140 (Fig. 1D).
hTERT(+) EC Lines Retain EC Characteristics--
Baseline
expression of von Willebrand factor and CD31(PECAM-1) and
cytokine-stimulated cell surface expression of inflammatory adhesion
molecules, ICAM, VCAM, and E-selectin are regarded as key markers
distinguishing ECs from other cell types both in vivo and
in vitro (14, 44). Similarly, binding and uptake of
acetylated LDL and formation of tubule-like structures in response to
matricellular signals also define important EC functions maintained
in vitro by primary ECs that have not lost their
differentiated phenotype (17). Therefore we have assessed the
hTERT-EC lines for EC marker expression and responses to cytokines and
matricellular proteins (Figs. 3 and
4 and Table II).
Morphogenetic responses were evaluated by exposing HUVEC parental mass
cell cultures at PDL 27 (Fig. 3A) and a representative hTERT(+) HUVEC clone at PDL 127 (Fig. 3B) to Matrigel. Both
cell populations responded similarly by efficiently forming
"angiogenic webs," whereas late passage, senescent PDL 50 HUVECs
(Fig. 3E) and a spontaneously transformed HUVEC line, ECV304
(Fig. 3F), did not. Similar results were obtained for both
parental HDMECs and hTERT(+) HDMECs exposed to 3D type I
collagen (Fig. 3, C and D), and we found that
these cells also form tubule-like structures in response to Matrigel.
Senescent HDMECs did not form tubules in 3D collagen. As in parental
cell lines, some variability in tubule pattern formation was apparent
among different hTERT-EC strains (see Table II).
Cell surface expression of PECAM-1 by unstimulated parental HUVECs and
an hTERT(+) HUVEC clone at PDL 120 (Fig. 4A) showed similar
90-95% immunoreactivity. Likewise, parental HDMEC and hTERT(+) HDMEC
lines showed high PECAM-1 reactivity (Fig. 4B). Expression
of Von Willebrand factor and LDL uptake also showed no differences
between parental and hTERT-EC lines (Table II). Basal and
TNF- hTERT-ECs Maintain Growth and Cell Cycle Control Patterns Similar
to Parental ECs--
We investigated the growth of hTERT(+) EC lines
and found no significant differences in their growth rates compared
with parental ECs prior to senescence. The growth curves shown in Fig.
5A are representative of all
large vessel hTERT-EC lines and indicate no alteration in growth rates
with continuous passage in vitro. Although mitotic rates
were not analyzed in detail, simultaneous growth curves of parental
HDMECs at PDL 10 and hTERT(+) HDMECs at PDL 65 generated by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
method (30) showed no significant differences during a 7-day period.
Similar to previous studies in human skin fibroblast and RPE lines
produced by hTERT expression (26, 27) hTERT(+) EC lines are
contact-inhibited and exhibited normal pRb phosphorylation patterns in
response to confluency-induced growth arrest (Fig. 5B). In
addition, no changes in pRb phosphorylation patterns were observed upon
growth arrest induced by either serum deprivation or hydroxyurea
treatment when hTERT(+) ECs were compared with parental EC controls
(Table II, data not shown). When anchorage-dependent growth
was assessed using the soft agar assay, ECV304 cells formed colonies
readily, whereas none of the hTERT-EC lines did (Fig. 5C).
Taken together, these data suggest that, contrary to viral oncogene-induced or spontaneously transformed cell lines, hTERT(+) EC
lines do not exhibit the growth or cell cycle control patterns of
neoplastic, transformed cells even after growing in vitro
for 2-5 times their respective life spans.
G banding and cytogenetic analyses showed that both parental HDMEC
preparations we used had a normal male, diploid karyotype, and this was
maintained upon hTERT immortalization (Fig.
6). Tetraploidy was observed in one
hTERT(+) HDMEC line, hTERT1, at PDL 140; it was not seen at PDL 50. Another hTERT(+) HDMEC line, hTERT3, had no tetraploidy at PDL 75. No
aneuploidy was observed in any parental or hTERT(+) HDMEC line. On the
other hand, karyotypic abnormalities were found in both large vessel
parental ECs, as well as hTERT(+) large vessel ECs, and these
abnormalities were similar to the polyploid changes observed in late
passage fibroblasts and hTERT(+) fibroblast lines (26). Parental large
vessel ECs had at least 40% aneuploidy at early PDL, which increased
to nearly 100% aneuploidy by late PDL. All large vessel hTERT(+) EC
lines also had 100% aneuploidy, and thus hTERT expression did not
prevent or reverse the genomic instability observed in parental ECs
before hTERT expression (see Table II).
Taken altogether, these results indicate that introduction of
telomerase into normal human ECs in vitro does not lead to
abnormal growth patterns, cell transformation, or genomic instability.
Decreased Programmed Cell Death in hTERT(+) ECs--
Recent
studies indicate that EC apoptosis is associated with important
vascular remodeling patterns under both physiologic and pathologic
conditions (45-50). Clarification of EC apoptotic mechanisms thus
represents an important therapeutic strategy in the management of
acute, chronic, and neoplastic diseases (51-53). Previous studies of
human dermal fibroblasts showed that senescent cells are more resistant
to apoptosis relative to young cells in vitro (54, 55).
Therefore, we monitored the basal apoptotic rate in HDMECs and found
that both early and late passage parental HDMECs showed lower nuclear
fragmentation relative to mid passage HDMECs (Fig.
7A), with differences reaching
statistical significance for PDL 15 versus both PDL 5 and
25. The effect of PDL on apoptosis in primary HDMEC cultures was
verified by flow cytometric analysis of Apo2.7 positivity, reflecting
the exposure of an early and specific mitochondrial apoptotic protein,
7A6 (38) (Fig. 7B). Two different hTERT-HDMEC lines showed
statistically significant differences in baseline apoptotic rates
versus each other, and both lines were comparable to early
and late passage parental HDMECs (Fig. 7, A and
B).
Next, we compared apoptosis after stimulation with several different EC
apoptotic inducers using the two hTERT-HDMEC lines and late passage,
presenescent parental HDMECs as controls. Four different conditions for
inducing EC apoptosis all showed the same result: hTERT(+) HDMECs
resisted apoptotic induction relative to primary HDMECs (Fig. 7,
C and D). Except for TNF- In using five different types of human ECs, we have demonstrated
the general applicability of using ectopic expression of hTERT to
bypass replicative senescence while maintaining EC phenotypic and
morphogenetic characteristics in vitro. Upon stable
transfection or retroviral transduction of hTERT, telomerase activity
was detectable in all ECs, and telomere lengths decreased with time in
culture and then stabilized. To date, both hTERT-expressing clones and mass cultures have achieved a PDL (PDL 50-160) 2.5-5 times that of
parental or control vector-transduced cells (PDL 30-50) and therefore
are considered "immortal" (43). All hTERT-EC clones and different
lines have been continuously passaged without evidence of altered
morphology or changes in growth patterns.
Detailed analysis of EC phenotypic patterns revealed several important
characteristics about hTERT-ECs. First, the various parental and
hTERT-EC lines are typical of "partially activated" endothelium
in vivo (14); however, the cell adhesion molecule expression
profiles of senescent primary ECs (Fig. 4 and Table II) resembled that
of inflammatory tissue (7-9). Second, hTERT-ECs underwent
morphogenetic differentiation to form capillary-like structures in
response to extracellular matrix signals, whereas senescent and
transformed ECs did not (Fig. 3), and this may reflect an age-related
functional defect in angiogenesis in vivo (1, 2). Third,
similar to previous reports in other cell types, hTERT expression
per se did not induce EC cytogenetic instability or a
transformed phenotype (26, 27). Normal karyotypes were found in
hTERT-HDMEC lines as in parental cells (Fig. 6 and Table II).
hTERT-HUVEC clones and mass EC cultures were contact-inhibited, did not
grow in soft agar, and exhibited appropriate pRb phosphorylation patterns in response to serum, cell density, and hydroxyurea-induced cell cycle arrest (Fig. 5, Table II). Finally, hTERT-HDMECs were more
resistant to apoptotic induction than senescent parental controls or
sham-transduced ECs (Fig. 7, C and D).
Altogether, these results suggest that hTERT-ECs behave more like early
passage, young ECs.
Telomere lengths in senescent ECs used in this study ranged between 5 and 7 kbp (data not shown), and our hTERT-HDMECs stabilized at 4-5 kbp
(Fig. 1C). Previous studies in ECs (56), human fibroblasts (35), and various human cells (57) have shown that the mean TRF at
senescence is approximately 4-7 kbp. hTERT immortalization of
fibroblasts and RPE resulted in an increase and/or stabilization of
telomere length to a size of >8 kbp (57). Thus, our hTERT-HUVEC clones
with mean TRFs of 2-2.5 kbp (Fig. 1D) are well below those previously reported, and yet these cells bypassed senescence and continue to divide. Our results with hTERT(+) HUVEC clones are similar,
however, to recent studies in hTERT(+) human fibroblast lines, which
show a similar pattern of decreasing TRF with increasing PDL beyond the
M2 crisis point (58). Possible reasons for these intrinsic differences
in telomere lengths may relate to either cell type-specific mechanisms
of telomere maintenance or threshold for functional telomerase of mass
cell cultures versus individual clones.
Several studies have shown that genetic abnormalities occur in large
vessel ECs (59, 60), but little is known about human microvascular EC
cytogenetic instability. Our hTERT(+) HDMEC lines remained diploid
after continuous passaging for 2-5 times their normal life spans. The
tetraploid changes we observed in hTERT1 at PDL 140 are similar to many
other human primary cells and immortalized cell lines that have been
continuously grown in vitro for extended periods (76-78).
However, the aneuploidy observed in both large vessel parental EC and
hTERT-EC lines (Table II) indicates that hTERT expression does not
appear to reverse these cytogenetic abnormalities. Because our
hTERT-HDMEC lines showed a maintenance of normal karyotypes, these
results suggest that hTERT expression per se does not induce
chromosomal instability in human ECs. Recent studies in the mTR null
mouse show critical interdependence of p53/p19, pRb/p16, p21, telomere
dysfunction, and cell survival beyond the "genetic catastrophe"
point (74, 75). Transformation into a neoplastic cell type in the mouse
appears to depend on tolerance of genetic instability requiring certain
adaptive responses, e.g. activation of oncogenes and/or telomerase,
inactivation of tumor suppressors, etc. Our studies in hTERT(+) large
vessel ECs show maintenance of normal growth rates and growth arrest
patterns and absence of colony formation even in the face of
cytogenetic instability at PDLs 2-4 times that of parental cells.
These data suggest that a functional p53-dependent DNA
damage checkpoint arrest pathway accompanying telomerase activation is
important in preventing neoplastic transformation of large vessel human ECs.
The karyotypically normal hTERT(+) HDMECs exhibit a distinct survival
advantage beyond that caused by hurdling the M1 senescence barrier
(61), as these cells resist induction of apoptosis relative to
senescent parental ECs under identical conditions. To our knowledge, this study is also the first to report EC apoptosis as a function of
PDL, and our results indicate that senescent ECs were resistant to
apoptosis relative only to midpassage primary ECs, not early passage
cells, as reported previously in fibroblasts (54, 55). We used only
confluent, growth-arrested cells for our apoptosis analyses as it is
known that proliferating cells are more susceptable to apoptosis than
are quiescent cells; however, unrepaired DNA and chromosomal damage are
also known to trigger apoptotic induction (62-64, 74, 75). Only
recently, it was found that DNA damage in the form of telomere
shortening can be linked to either apoptosis or senescence, depending
on a functional p53-dependent DNA checkpoint arrest pathway
(65, 74, 75). A relationship between telomerase and apoptosis is
apparent and it is known that telomerase functions to repair
chromosomal damage induced by a wide variety of different agents that
cause DNA strand breaks (66-69). Telomerase could thus be influencing
nuclear fragmentation events observed in apoptosis, and several other
studies support an inverse relationship between telomerase activity and
programmed cell death (70-73).
Our results also support an inverse relationship between telomerase
activity and apoptosis. The mechanism(s) of apoptotic resistance in
telomerase-activated ECs is unclear, and further studies are in
progress to clarify it. From the perspective of both potential
therapeutic benefit and clarification of these possible mechanistic
pathways, the development of an in vivo angiogenesis and
vascular remodeling system incorporating hTERT(+) HDMECs becomes of
paramount importance, and such studies are currently under way.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
(20 ng/ml) for 15 h before the assay. For detection of the early
apoptotic mitochondrial protein 7A6, monoclonal antibody Apo2.7 (38)
reactivity was measured after the cells were treated with TNF-
(50 ng/ml) + actinomycin D (1 µg/ml), lipopolysaccharide (100 ng/ml) + cycloheximide (50 µg/ml), or UVC light (255 nm for 0.3 min) 16 h
prior to the experiments. Another group of cells were serum-starved for
40 h. The cells were incubated with either
phosphatidylethanolamine-conjugated primary antibody or unconjugated
primary antibody + phosphatidylethanolamine-conjugated secondary
antibody at 37 °C. For the annexin V assay, we used all reagents and
protocols according to the manufacturer (Roche Molecular Biochemicals).
The data were collected and analyzed with CellQuest (Becton Dickinson)
or Coulter EPICS Elite ESP system.
-Galactosidase Staining--
SA
-galactosidase staining was performed as previously published (41).
Briefly, primary early passage or senescent and hTERT(+) ECs were
washed in phosphate-buffered saline and then fixed in 0.5%
glutaraldehyde for 10 min. The cells were washed in phosphate-buffered
saline twice and incubated in SA
-galactosidase stain solution
overnight. Color pictures were taken with Zeiss inverted microscope.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (38K):
[in a new window]
Fig. 1.
Telomerase activity and telomere length in
human endothelial cells after hTERT expression. A,
telomerase activity measured by the TRAP assay (see under "Materials
and Methods") was detected in both early (PDL 5) parental HDMECs PD5
and all hTERT-ECs from as little as 1000 cell equivalents, but was not
detected in middle or late passage parental, sham-infected (LacZ) or
heat-treated (HT) hTERT-HUVECs, hTERT-HAECs, and
hTERTHDMECs. B, hTERT-HDMEC telomerase activity was
quantified using PCR-ELISA and showed persistent activity up to PDL
100, at levels ranging between 80 and 120% of that of the embryonic
kidney tumor cell line, 293. Similar results were obtained from two
other human cell strains, hTERT-HCAECs and hTERT-HSVECs. C,
TRF length of DNA from hTERT-HDMECs at different PDLs showing loss of
telomeric DNA from approximately 9 to 4 kbp spanning PDL 100. D, mean TRF length at the indicated PDLs for four
representative hTERT-HUVEC clones showing stabilization of telomere
length at approximately 2.5 kbp.
-galactosidase
staining (Table II). By contrast, all
hTERT-EC lines resembled young primary ECs in their morphology and
growth response, with little or no staining with SA
-galactosidase activity. Thus, ectopic expression of hTERT in ECs extended the replicative life span of all EC strains examined to over twice that of
primary ECs, technically defining these hTERT-EC lines as immortalized
(43).
Maximal replication life span of endothelial cells

View larger version (92K):
[in a new window]
Fig. 2.
Cell morphology of continuously passaged
parental and hTERT-HDMECs as a function of PDL. A early
passage, primary parental HDMECs at PDL 6; B, senescent
parental HDMEC at PDL 30. C and D,
sham-transduced (LacZ) parental HDMECs at PDL 6 (C) and at
PDL 30 (D). E and F, hTERT-HDMECs at
PDL 6 (E) and at PDL 30 (F). Bar, 10 µm.
Phenotype, function, and karyotype of hTERT(+)-EC cultures
, negative from the assay; ND, not determined; N, normal; AB,
abnormal;
, decrease.

View larger version (92K):
[in a new window]
Fig. 3.
Morphogenetic responses of different EC types
exposed to Matrigel and 3D collagen. A, early passage
primary HUVECs (PDL 27) grown on Matigel formed angiogenic webs as
efficiently as hTERT-HUVECs at PDL 127 (B). Similarly, early
passage (PDL 5) primary HDMECs formed tubule-like structures after 3D
collagen exposure (C), as did hTERT-HDMECs at PDL 50 (D). However, both senescent HUVECs (PDL 50) (E)
and the transformed HUVEC line ECV304 (F) failed to respond
to Matrigel. Bar, 10 µm.

View larger version (37K):
[in a new window]
Fig. 4.
Flow cytometric analysis of primary ECs and
hTERT-ECs for constitutive PECAM-1 and
TNF-
-inducible ICAM-1 cell surface
expression. A and B, both parental and
hTERT-HUVECs and hTERT-HDMECs expressed >90% PECAM (open
areas, normal IgG; shaded areas, anti-PECAM IgG).
HUVECs (parental and hTERT) (A) and ECV304 (C)
expressed little or no basal ICAM (open areas), whereas
HDMECs (parental and hTERT) (B) and senescent HUVECs (PDL
50) (C) had higher basal ICAM levels (5-15%). Irrespective
of basal levels, ICAM expression was strongly induced in both parental
and hTERT-HUVECs and-HDMECs (A and B) by 20 ng/ml
of TNF-
(shaded area), whereas ICAM expression in
senescent HUVECs and ECV304 (C) was not induced by
TNF-
.
-stimulated cell surface expression of ICAM-1, VCAM-1, and
E-selectin were similar in both parental and hTERT-EC lines (Fig. 4,
A and B, Table II). By contrast, senescent HUVECs expressed high level of ICAM-1, which was not stimulated by TNF-
, and ECV304 showed both low baseline and stimulated ICAM expression. Taken together, the data show that hTERT(+) EC lines continuously passaged in vitro for 3-5 times the normal replicative life
span of primary ECs exhibit both the functional and differentiated phenotype of early passage, primary ECs.

View larger version (43K):
[in a new window]
Fig. 5.
Growth and cell cycle control patterns of
hTERT(+) ECs versus primary ECs. A,
growth curves of four different hTERT(+) HUVEC clones and a single HAEC
mass culture remained linear following continuous growth in
vitro for 2-3 times the PDL of their respective parental EC
controls. B, immunoblotting of pRb in primary HUVECs, HAECs,
and HDMECs (upper panel) at subconfluency (S) or
72 h at confluency (C) showed comparable
phosphorylation patterns to hTERT(+) ECs (lower panel).
C, representative photomicrographs of colony formation in
soft agar (see under "Materials and Methods"). None of our hTERT(+)
EC strains (HAECs at PDL 127 used as an example) (right)
formed colonies in soft agar, whereas the ECV304 transformed cell line
did (left).

View larger version (27K):
[in a new window]
Fig. 6.
Karyotype of the hTERT(+) HDMEC line hTERT1
at PDL 50. Chromosomes were analyzed by GTW banding (see under
"Materials and Methods"). The two parental HDMEC lines (at PDL 10 and 5, respectively) and both hTERT(+) HDMEC lines (hTERT1 and hTERT3
at PDL 50 and 75, respectively) all had normal diploid 46, XY male
karyotype (20 metaphases for each). However, hTERT1 at PDL 140 were
mostly tetraploid 92, XX YY (see Table II).

View larger version (31K):
[in a new window]
Fig. 7.
HDMEC programmed cell death as measured by
nuclear fragmentation cell death ELISA (A and
C) and flow cytometric analysis of mitochondrial
Apo2.7 positivity (B and D) (see
under "Materials and Methods"). A and B,
basal levels of apoptosis in primary parental HDMECs showed a dynamic
change as a function of PDL with higher rates at mid passage (PDL 15, double asterisks) versus early (PDL 5) or late
(PDL 25). Basal apoptotic rates of two different hTERT-HDMEC lines
(hTERT1 and hTERT3) remained stable with increasing PDL, but the HDMEC3
line was significantly less apoptotic versus both primary
and hTERT-HDMEC1 (single asterisks). C, following
induction of apoptosis by treatment with either TNF-
(0.1 µg/ml) + actinomycin D (1 µg/ml), lipopolysaccharide (0.1 µg/ml) + cycloheximide (50 µg/ml), UVC exposure (255 nm for 0.3 min), or serum
starvation (40 h), both hTERT-HDMEC lines exhibited significantly lower
nuclear fragmentation (asterisks) versus
senescent primary HDMEC controls. D, the same trend was
found for Apo2.7 flow cytometry; however, only
lipopolysaccharide-induced apoptosis in hTERT-HDMEC1 reached
statistical significance (asterisk). Statistical
significance, <0.05. Experiments were repeated three times on
hTERT-HDMECs. Results shown are represenative of three
experiments.
+ actinomycin D
induction in hTERT1 cells, both hTERT-HDMEC lines expressed statistically significant lower nuclear fragmentation versus
controls in response to all treatments. Lipopolysaccharide + cycloheximide induction showed significantly decreased Apo2.7
expression in hTERT-HDMEC1 versus control, whereas other
treatments did not reach statistical significance. The hTERT-HDMEC3
line that exhibited lower baseline apoptosis generally showed the
lowest stimulated apoptotic rates. UV light-induced nuclear
fragmentation and Apo2.7 expression appeared to reveal the most
dramatic differences between primary and both hTERT HDMEC lines.
Experiments assessing apoptosis resistance in large vessel hTERT(+) EC
lines are under way, but preliminary studies using annexin V expression
in HAECs after TNF-
+ actinomycin D induction showed a similar
apoptosis resistance (data not shown).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank DanNing Zhang, David Lao, Ken Rolloma, Usha Nagavarapu, Bryan Gardner, Sharon Wong, XuRong Jiang, and Orlena Tam for expert technical assistance, Jackie Walker for administration assistance, and Dr. Woody Wright, University of Texas, Southwestern Medical Center (Dallas, Texas), for providing us with the retroviral vector pBabe-hTERT. Prof. Marvin A. Karasek is gratefully acknowledged for advice in the cultivation of HDMECs, and we thank Paul A. Khavari for help with the retroviral infection protocol.
| |
FOOTNOTES |
|---|
* This work was supported by NIH PO-1 AR44012, the Carl J. Herzog Foundation, and the Dermatology Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ The first two authors contributed equally to this work.
** A Terman Fellow. To whom correspondence should be addressed: Dept. of Dermatology, MSLS Bldg. P205, Stanford University School of Medicine, Stanford, CA 94305-5486. Tel.: 650-725-2209; Fax: 650-723-8762; E-mail: gbh@leland.stanford.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: EC, endothelial cell; HDMEC, human dermal microvascular EC; HUVEC, human umbilical vein EC; HSVEC, human saphenous vein EC; HAEC, human aortic EC; HCAEC, human coronary arterial EC; PECAM, platelet EC adhesion molecule; PDL, population doubling; hTERT, human telomerase reverse transcriptase; RPE, retinal pigment epithelial; TRAP, telomeric repeat amplification protocol; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; RT, reverse transcription; TRF, terminal restriction fragment; ICAM, intercellular adhesion molecule; TNF, tumor necrosis factor; 3D, three-dimensional; SA, senescence-associated; kbp, kilobase pair(s); pRb, retinoblastoma protein; LDL, low density lipoprotein; VCAM, vascular cell adhesion molecule.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Pili, R.,
Guo, Y.,
Chang, J.,
Nakanishi, H.,
Martin, G. R.,
and Passaniti, A.
(1994)
J. Natl. Cancer Inst.
86,
1303-1314 |
| 2. | Rivard, A., Fabre, J. E., Silver, M., Chen, D., Murohara, T., Kearney, M., Magner, M., Asahara, T., and Isner, J. M. (1999) Circulation 99, 111-120[Medline] [Order article via Infotrieve] |
| 3. | Cooper, L. T., Cooke, J. P., and Dzau, V. J. (1994) J. Gerontol. 49, B191-B196[Medline] [Order article via Infotrieve] |
| 4. | Kannel, W., and Gordon, T. (1980) in Cardiovascular Risk Factors in the Aged: The Farmingham Study (Haynes, S. , and Feinleib, S., eds) , pp. 65-98, National Institutes of Health, Bethesda, MD |
| 5. | West, M. D. (1994) Arch. Dermatol. 130, 87-95[Abstract] |
| 6. | Campisi, J. (1996) Cell 84, 497-500[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Maier, J. A., Statuto, M., and Ragnotti, G. (1993) Exp. Cell Res. 208, 270-274[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Comi, P., Chiaramonte, R., and Maier, J. A. (1995) Exp. Cell Res. 219, 304-308[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Maier, J. A.,
Voulalas, P.,
Roeder, D.,
and Maciag, T.
(1990)
Science
249,
1570-1574 |
| 10. | Tokunaga, O., Yamada, T., Fan, J. L., and Watanabe, T. (1991) Am. J. Pathol. 138, 941-949[Abstract] |
| 11. | Carrol, T., and Schroff, S. (1991) J. Clin. Invest. 87, 1002-1009 |
| 12. | Sato, I., Morita, I., Kaji, K., Ikeda, M., Nagao, M., and Murota, S. (1993) Biochem. Biophys. Res. Commun. 195, 1070-1076[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Sholley, M. M., and Cotran, R. S. (1976) Am. J. Anat. 147, 243-254[CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Cines, D. B.,
Pollak, E. S.,
Buck, C. A.,
Loscalzo, J.,
Zimmerman, G. A.,
McEver, R. P.,
Pober, J. S.,
Wick, T. M.,
Konkle, B. A.,
Schwartz, B. S.,
Barnathan, E. S.,
McCrae, K. R.,
Hug, B. A.,
Schmidt, A. M.,
and Stern, D. M.
(1998)
Blood
91,
3527-3561 |
| 15. | Klagsbrun, M., and D'Amore, P. A. (1991) Annu. Rev. Physiol. 53, 217-239[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Folkman, J. (1995) Nat. Med. 1, 27-30[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Bicknell, R. (1996) in Endothelial Cell Culture (Bicknell, R., ed) , p. xii and 136, Cambridge University Press, Oxford, United Kingdom |
| 18. | Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., and Lawley, T. J. (1992) J. Invest. Dermatol. 99, 683-690[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Dubois, N. A., Kolpack, L. C., Wang, R., Azizkhan, R. G., and Bautch, V. L. (1991) Exp. Cell Res. 196, 302-313[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Candal, F. J., Rafii, S., Parker, J. T., Ades, E. W., Ferris, B., Nachman, R. L., and Kellar, K. L. (1996) Microvasc. Res. 52, 221-234[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Fontijn, R., Hop, C., Brinkman, H. J., Slater, R., Westerveld, A., van Mourik, J. A., and Pannekoek, H. (1995) Exp. Cell Res. 216, 199-207[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Cockerill, G. W., Meyer, G., Noack, L., Vadas, M. A., and Gamble, J. R. (1994) Lab. Invest. 71, 497-509[Medline] [Order article via Infotrieve] |
| 23. | Watanabe, Y., Lee, S. W., Detmar, M., Ajioka, I., and Dvorak, H. F. (1997) Oncogene 14, 2025-2032[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Watanabe, Y., and Dvorak, H. F. (1997) Exp. Cell Res. 233, 340-349[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Bodnar, A. G.,
Ouellette, M.,
Frolkis, M.,
Holt, S. E.,
Chiu, C. P.,
Morin, G. B.,
Harley, C. B.,
Shay, J. W.,
Lichtsteiner, S.,
and Wright, W. E.
(1998)
Science
279,
349-352 |
| 26. | Jiang, X., Jimenez, G., Chang, E., Frolkis, M., Kusler, B., Sage, M., Beeche, M., Bodnar, A., Wahl, G., TlstyTlsty, T., and Chiu, C.-P. (1999) Nat. Genet. 21, 111-114[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Morales, C., Holt, S., Ouellette, M., Kaur, K., Yan, Y., Wilson, K., White, M., Wright, W., and Shay, J. (1999) Nat. Genet. 21, 115-118[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., and Klingelhutz, A. J. (1998) Nature 396, 84-88[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Karasek, M. A. (1989) J. Invest. Dermatol. 93 Suppl. 2, 33S-38S[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Romero, L. I., Zhang, D. N., Herron, G. S., and Karasek, M. A. (1997) J. Cell. Physiol. 173, 84-92[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Morgenstern, J. P.,
and Land, H.
(1990)
Nucleic Acids Res.
18,
3587-3596 |
| 32. | Kinsella, T. M., and Nolan, G. P. (1996) Hum. Gene Ther. 7, 1405-1413[Medline] [Order article via Infotrieve] |
| 33. |
Kim, N. W.,
and Wu, F.
(1997)
Nucleic Acids Res.
25,
2595-2597 |
| 34. | Harley, C. B., Futcher, A. B., and Greider, C. W. (1990) Nature 345, 458-460[CrossRef][Medline] [Order article via Infotrieve] |
| 35. |
Allsopp, R. C.,
Vaziri, H.,
Patterson, C.,
Goldstein, S.,
Younglai, E. V.,
Futcher, A. B.,
Greider, C. W.,
and Harley, C. B.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10114-10118 |
| 36. | Vaziri, H., Schächter, F., Uchida, I., Wei, L., Zhu, X., Effros, R., Cohen, D., and Harley, C. B. (1993) Am. J. Hum. Genet. 52, 661-667[Medline] [Order article via Infotrieve] |
| 37. | Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W., and Harley, C. B. (1992) J. Mol. Biol. 225, 951-960[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Koester, S. K., Roth, P., Mikulka, W. R., Schlossman, S. F., Zhang, C., and Bolton, W. E. (1997) Cytometry 29, 306-312[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Barch, M. J., and Knutsen, T. (eds) (1997) The AGT Cytogenetics Laboratory Manual , Vol. xiii , p. 666, Lippincott-Raven, New York |
| 40. | Seabright, M. (1971) Lancet 2, 971-972[Medline] [Order article via Infotrieve] |
| 41. |
Dimri, G. P.,
Lee, X.,
Basile, G.,
Acosta, M.,
Scott, G.,
Roskelley, C.,
Medrano, E. E.,
Linskens, M.,
Rubelj, I.,
Pereira-Smith, O.,
et al..
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9363-9367 |
| 42. | Hsiao, R., Sharma, H. W., Ramakrishnan, S., Keith, E., and Narayanan, R. (1997) Anticancer Res. 17, 827-832[Medline] [Order article via Infotrieve] |
| 43. | Shay, J. W., Pereira-Smith, O. M., and Wright, W. E. (1991) Exp. Cell Res. 196, 33-39[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Petzelbauer, P., Schechner, J., and Pober, J. (1999) in Endothelium: Dermatology in General Medicine (Freedberg, I. M. , Eisen, A. Z. , Wolff, K. , Austen, K. F. , Goldsmith, L. A. , Katz, S. I. , and Fitzpatrick, T. B., eds), Ed. 5, Vol. 1 , pp. 305-320, McGraw-Hill |
| 45. | Brooks, P., Montgomery, A., Rosenfeld, M., Reisfeld, R., Hu, T., Klier, G., and Cheresh, D. (1994) Cell 79, 1157-1164[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Lang, R., Lustig, M., Francois, F., Sellinger, M., and Plesken, H. (1994) Development 120, 3395-3403[Abstract] |
| 47. | Gobé, G., Browning, J., Howard, T., Hogg, N., Winterford, C., and Cross, R. (1997) J. Struct. Biol. 118, 63-72[CrossRef][Medline] [Order article via Infotrieve] |
| 48. | Sgonc, R., Grushwitz, M., Dietrich, H., Recheis, H., Gershwin, M., and Wick, G. (1996) J. Clin. Invest. 98, 785-792[Medline] [Order article via Infotrieve] |
| 49. | Kaplan, H. J., Leibole, M. A., Tezel, T., and Ferguson, T. A. (1999) Nat. Med. 5, 292-297[CrossRef][Medline] [Order article via Infotrieve] |
| 50. | Pollman, M. J., Naumovski, L., and Gibbons, G. H. (1999) J. Cell. Physiol. 178, 359-370[CrossRef][Medline] [Order article via Infotrieve] |
| 51. | Karsan, A. (1998) Tumor Necrosis Factor and Endothelial Cell Death , Vol. 8 , pp. 19-24, Elsevier Science Publishing Co., Inc., New York |
| 52. |
Nor, J.,
Joan, C.,
Mooney, D.,
and Polverini, P.
(1999)
Am. J. Pathol.
154,
375-384 |
| 53. |
Claesson-Welsh, L.,
Welsh, M.,
Ito, N.,
Anand-Apte, B.,
Soker, S.,
Zetter, B.,
O'Reilly, M.,
and Folkman, J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5579-5583 |
| 54. |
Wang, E.
(1995)
Cancer Res.
55,
2284-2292 |
| 55. | Chang, E. H., Jang, Y. J., Hao, Z., Murphy, G., Rait, A., Fee, W. E., Jr., Sussman, H. H., Ryan, P., Chiang, Y., and Pirollo, K. F. (1997) Arch. Otolaryngol.-Head Neck Surg. 123, 507-512[Abstract] |
| 56. |
Chang, E.,
and Harley, C. B.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11190-11194 |
| 57. |
Counter, C. M.,
Hahn, W. C.,
Wei, W.,
Caddle, S. D.,
Beijersbergen, R. L.,
Lansdorp, P. M.,
Sedivy, J. M.,
and Weinberg, R. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
14723-14728 |
| 58. |
Zhu, J.,
Wang, H.,
Bishop, J.,
and Blackburn, E.
(1999)
Proc. Natl Acad. Sci. U. S. A.
96,
3723-3728 |
| 59. | Johnson, T. E., Umbenhauer, D. R., Hill, R., Bradt, C., Mueller, S. N., Levine, E. M., and Nichols, W. W. (1992) J. Cell. Physiol. 150, 17-27[CrossRef][Medline] [Order article via Infotrieve] |
| 60. | Nichols, W. W., Buynak, E. B., Bradt, C., Hill, R., Aronson, M., Jarrell, B. E., Mueller, S. N., and Levine, E. M. (1987) J. Cel. Physiol. 132, 453-462[CrossRef][Medline] [Order article via Infotrieve] |
| 61. | Harley, C., Vaziri, H., Counter, C., and Allsopp, R. (1992) Exp. Gerontol. 27, 375-382[CrossRef][Medline] [Order article via Infotrieve] |
| 62. | Meikarnatz, W., and Schlegel, R. (1995) J. Cell. Biochem. 58, 160-174[CrossRef][Medline] [Order article via Infotrieve] |
| 63. | King, K. L., and Cidlowski, J. A. (1995) J. Cell. Biochem. 58, 175-180[CrossRef][Medline] [Order article via Infotrieve] |
| 64. | Kasten, M., and Giordano, A. (1998) Cell Death Differ. 5, 132-140[CrossRef][Medline] [Order article via Infotrieve] |
| 65. | Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., and de Lange, T. (1999) Science 283, 321-324[CrossRef] |
| 66. | Wilkie, A. O., Lamb, J., Harris, P. C., Finney, R. D., and Higgs, D. R. (1990) Nature 346, 868-871[CrossRef][Medline] [Order article via Infotrieve] |
| 67. | Morin, G. B. (1991) Nature 353, 454-456[CrossRef][Medline] [Order article via Infotrieve] |
| 68. | Flint, J., Craddock, C. F., Villegas, A., Ventley, D. P., Williams, H. J., Galandello, R., Cao, A., Wood, W. g., Ayyub, H., and Higgs, D. R. (1994) Am. J. Hum. Genet. 55, 505-512[Medline] [Order article via Infotrieve] |
| 69. | Hande, M. P., Lansdorp, P. M., and Natarajan, A. T. (1998) Mutat. Res. 404, 205-214[Medline] [Order article via Infotrieve] |
| 70. | Burger, A. M., Double, J. A., and Newell, D. R. (1997) Eur. J. Cancer 33, 638-644 |
| 71. |
Kondo, S.,
Tanaka, Y.,
Kondo, Y.,
Hitomi, M.,
Barnett, G. H.,
Ishizaka, Y.,
Liu, J.,
Haqqi, T.,
Nishiyama, A.,
Villeponteau, B.,
Cowell, J. K.,
and Barna, B. P.
(1998)
FASEB J.
12,
801-811 |
| 72. |
Mandal, M.,
and Kumar, R.
(1997)
J. Biol. Chem.
272,
14183-14187 |
| 73. |
Fu, W.,
Begley, J.,
Killen, M.,
and Mattson, M.
(1999)
J. Biol. Chem.
274,
7264-7271 |
| 74. | Greenberg, R., Chin, L., Femino, A., Lee, K., Gottlieb, G., Singer, R., Greider, C., and DePinho, R. (1999) Cell 97, 515-525[CrossRef][Medline] [Order article via Infotrieve] |
| 75. | Chin, L., Artandi, S., Shen, Q., Tam, A., Lee, S., Gottlieb, G., Greider, C., and DePinho, R. (1999) Cell 97, 527-538[CrossRef][Medline] [Order article via Infotrieve] |
| 76. | Gordon, D., Mohai, L., and Schwartz, S. (1986) Circ. Res. 59, 633-644[Abstract] |
| 77. | Kaji, K., and Matsuo, M. (1981) Exp. Cell Res. 131, 410-412[CrossRef][Medline] [Order article via Infotrieve] |
| 78. | Matsumura, T. (1980) Adv. Exp. Med. Biol. 129, 31-38[Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
P. Au, L. M. Daheron, D. G. Duda, K. S. Cohen, J. A. Tyrrell, R. M. Lanning, D. Fukumura, D. T. Scadden, and R. K. Jain Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels Blood, February 1, 2008; 111(3): 1302 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Gallegos and R. M. Bolman III Stem Cell Induced Regeneration of Myocardium Card. Surg. Adult, January 1, 2008; 3(2008): 1657 - 1668. [Full Text] |
||||
|
|